Stock NUVL NUVALENT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Nuvalent, Inc.

Equities

NUVL

US6707031075

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
66.86 USD +1.20% Intraday chart for Nuvalent, Inc. +6.53% -9.15%
Apr. 17 Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing MT
Apr. 17 Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing
MT
Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target
MT
Nuvalent Insider Sold Shares Worth $2,566,479, According to a Recent SEC Filing
MT
North American Morning Briefing : Stocks Seen -2-
DJ
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing
MT
Leerink Partners Upgrades Nuvalent to Outperform From Market Perform, Raises Price Target to $110 From $69
MT
Nuvalent Insider Sold Shares Worth $3,032,528, According to a Recent SEC Filing
MT
Nuvalent Insider Sold Shares Worth $1,550,229, According to a Recent SEC Filing
MT
BMO Capital Raises Price Target on Nuvalent to $102 From $93, Maintains Outperform Rating
MT
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
AQ
Nuvalent's Non-Small Cell Lung Cancer Drug Candidate Gets FDA Breakthrough Therapy Designation
MT
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Nuvalent, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Baird Initiates Nuvalent With Outperform Rating, Price Target is $105
MT
Nuvalent Starts Phase 2 Part of Clinical Trial of Potential Lung Cancer Treatment
MT
Wedbush Raises Nuvalent's Price Target to $99 From $82, Maintains Outperform Rating
MT
Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors
CI
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PR
Nuvalent Announces 'OnTarget 2026' Operating Plan and Key Anticipated Milestones
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NUVL Stock
  4. News Nuvalent, Inc.